SCHEMBL802472

SCHEMBL802472

Cc1nc(Nc2nc(-c3ccccc3C)nc3c2OCC3)n[nH]1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3A P49840 1/20 0.43
GSK3B P49841 1/20 0.43
ALDH1A1 P00352 6/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
CYP1A2 P05177 11/20 0.35
CYP3A4 P08684 10/20 0.35
HSD17B10 Q99714 7/20 0.35
CLK4 Q9HAZ1 6/20 0.35
CYP2D6 P10635 6/20 0.35
ALOX15 P16050 5/20 0.35
CYP2C19 P33261 5/20 0.35
USP2 O75604 4/20 0.35
TSHR P16473 4/20 0.34
MAPK1 P28482 2/20 0.34
LMNA P02545 3/20 0.34
TDP1 Q9NUW8 1/20 0.33
AXL P30530 1/20 0.32
GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL801833 0.94 GSK3A (0.42) GSK3AGSK3BALDH1A1SMN1; SMN2NPC1
SCHEMBL802220 0.93 GSK3A (0.41) GSK3AGSK3BALDH1A1SMN1; SMN2NPC1
SCHEMBL805633 0.87 GSK3A (0.40) GSK3AGSK3BALDH1A1CYP1A2CYP3A4
SCHEMBL10267503 0.81 GSK3A (0.39) GSK3AGSK3BALDH1A1CYP1A2CYP3A4
SCHEMBL805635 0.80 GSK3A (0.38) GSK3AGSK3BALDH1A1CYP1A2CYP3A4
SCHEMBL805607 0.80 GSK3A (0.45) GSK3AGSK3BALDH1A1SMN1; SMN2NPC1
SCHEMBL802053 0.76 GSK3A (0.46) GSK3AGSK3BALDH1A1CYP1A2CYP3A4
SCHEMBL802192 0.75 GSK3A (0.75) GSK3AGSK3BALDH1A1SMN1; SMN2CYP1A2
SCHEMBL12653560 0.71 GSK3A (0.53) GSK3AGSK3BALDH1A1SMN1; SMN2NPC1
SCHEMBL802474 0.71 GSK3A (0.42) GSK3AGSK3BALDH1A1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633210-B2 Triazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-21 US disclosed
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, GSK3A, CDK19 GSK3A 2/4885GSK3B 1/4885ALDH1A1 4768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.